MB2 Dental: The 800-Practice Dental Partnership

Most dental roll-ups buy a practice, employ the dentist, and fold the office into a corporate brand. MB2 Dental built its entire pitch on the opposite promise: the dentist keeps the keys. That single design choice — letting affiliated doctors hold real equity in their own practices rather than trading it for a sliver of a holding company — is why MB2 calls itself a "Dental Partnership Organization" (DPO) instead of a Dental Service Organization (DSO), and it is the lens through which any investor should read the company.

Overview

MB2 Dental (legally MB2 Dental Solutions LLC) is a Carrollton, Texas–based platform that provides centralized business support — billing, HR, marketing, payer negotiation, procurement, and technology — to a national network of dentist-owned practices. It was founded in 2007 by Dr. Chris Steven Villanueva ("Dr. V"), a practicing dentist who still serves as CEO, and the company's own About page describes it as "the first and fastest-growing dental partnership organization (DPO)."¹

By the company's year-end 2025 reporting, MB2 had surpassed 800 affiliated practices across 45 states, supporting roughly 1,900 doctors and 12,500 team members.² The company reported roughly 2.1 million patients at mid-2025 and 4.5 million patient visits across full-year 2025 — note that visits and unique patients are different measures, and MB2 has reported them in different periods. Those figures place it firmly in the top tier of U.S. dental consolidators — the fourth-largest of the five platforms most investors track, behind Heartland, Aspen, and PDS Health but ahead of Smile Brands. What sets it apart is less its size than its ownership architecture, which it has used as both a recruiting tool for dentists and a selling point for three successive private-equity sponsors.

For an investor, MB2 sits at an interesting intersection: a fast-growing, heavily capitalized platform riding the same consolidation tailwind as its peers, but with a structural story that complicates the usual roll-up math. This profile is independent and not affiliated with MB2; figures attributed to the company are flagged as such, because — as is typical in this private, closely held corner of healthcare — most quantitative claims about MB2 ultimately originate with MB2 itself.

Company Snapshot

• Founded: 2007 — company-reported, and corroborated by independent market and financial sources.³
• Founder & CEO: Dr. Chris Steven Villanueva
• Headquarters: 2403 Lacy Lane, Carrollton, Texas (Dallas metro); the company markets itself as "Dallas-based"
• Model: Dental Partnership Organization (DPO) — doctor-equity joint ventures
• Scale (year-end 2025, company-reported): 800+ practices, 45 states, ~1,900 doctors, 12,500 team members
• Lead investors: Charlesbank Capital Partners (controlling, since 2021); Warburg Pincus (strategic, since 2024); KKR (primary lender)
• Most recent valuation: enterprise value in excess of $3.5 billion (reported at the November 2024 Warburg Pincus investment)

Footprint Analysis

MB2's headline numbers are best read as a trajectory rather than a single snapshot, because the company has reported a clean, dated progression at almost every milestone. Its practice count moved from 663 practices across 39 states at year-end 2023, to "more than 700" across 44 states by December 10, 2024, when Iowa became its 44th state, to "more than 750" in early 2025 when Hawaii (via a partnership with Hawaii Endodontics) became the 45th state, to its 800th practice in September 2025, marked by the acquisition of The Smile Lodge, a three-location pediatric group in New York's Capital Region.¹

One receipt deserves a caveat. MB2 counts "practices," not office locations — and those are not the same thing. The Smile Lodge transaction, treated as the single "800th practice," actually brought three physical offices into the network. Because MB2 does not publish a count of distinct clinical sites, the honest reading is that the number of patient-facing offices is a number above 800, by an unknown margin — practice count is a floor, not a ceiling. Investors modeling per-location economics should treat the 800 figure as conservative on locations and should not assume one practice equals one chair-bearing office.

Geographic reach has expanded steadily: from 23 states in 2020 (as reported by trade coverage drawing on MB2 data), to "more than 35" in 2022, to 39 in 2023, to 45 by early 2025.² MB2 does not publish the full 45-state list, but specific states can be confirmed from individual partnership announcements (Ohio, North Carolina, New Hampshire in 2022; Massachusetts, South Carolina, Vermont, West Virginia, Iowa in 2024; Hawaii in 2025) plus Texas, where the company is headquartered. A 2023 company breakdown of its then-663 practices — 451 general, 117 orthodontic, 47 pediatric, 16 endodontic, 12 periodontic, and 20 multispecialty — shows a general-dentistry core with a meaningful specialty overlay, the kind of mix that supports internal referrals.

Growth History

MB2's first decade was largely organic. The company's narrative — that the model "resonated" with colleagues and grew through dentist referrals — describes a founder-and-physician-owned business that scaled on peer trust rather than acquisition capital through roughly the mid-2010s. Institutional money entered in three distinct waves, and each was framed as a "recapitalization" that returned cash to existing shareholders, including doctor-partners:

• September 2017 — Sentinel Capital Partners. Sentinel announced a platform investment in MB2 (its sixth dental platform), describing the company as "a rapidly-growing dental service organization with a unique physician-centric ownership model."² Terms were not disclosed. This is treated as MB2's first recapitalization.
• January 2021 — Charlesbank Capital Partners. Charlesbank's Fund IX took a controlling interest, with management co-investing and Sentinel exiting.³ Deal value was not disclosed, but the transaction was financed in part by a roughly $2.344 billion debt facility led by KKR, per industry deal coverage drawing on KKR disclosures.² This kicked off MB2's most aggressive growth phase.
• November 13, 2024 — Warburg Pincus. Warburg made a $525 million strategic investment at a total enterprise value in excess of $3.5 billion, described by MB2 as its "third recapitalization in seven years." Charlesbank remained a significant shareholder and KKR continued as lender. These figures are consistent across the company's own disclosures and independent corroboration.²

A note on a common point of confusion: MB2's 2021 recapitalization was the Charlesbank deal, while Warburg Pincus is the 2024 sponsor — not, as is sometimes loosely cited, a 2021 entrant. The $3.5 billion-plus enterprise value is the only widely disclosed valuation in MB2's history; the 2017 and 2021 deal values remain private. Third-party market data estimates cumulative capital raised at roughly $2.494 billion, though that figure appears to blend debt and equity.³

Business Model

This is where the DPO label earns its keep — or doesn't, depending on how literally you read it.

In a conventional DSO, dentists who sell typically take cash plus, in some cases, a minority stake in the parent holding company ("HoldCo"), while relinquishing equity in their own practice. MB2's pitch inverts that. In its preferred joint-venture (JV) structure, the doctor and MB2 both hold equity directly in the practice entity and split profits pro rata, with each funding their pro-rata share of capital investments. MB2 also describes a "dual-equity" arrangement in which doctors hold equity in both their own practice and the parent company — so that when a recapitalization happens at the top (as in 2021 and 2024), doctor-partners can monetize alongside the institutional owners. That alignment — practice-level ownership plus parent-level upside — is the core of the recruiting and retention story.

Two honest caveats temper the marketing. First, MB2 does not disclose the percentage of equity doctors retain; it leans on phrases like "meaningful equity" and "owner mindset," and the split almost certainly varies by deal. Second, beneath the partnership branding, MB2's operating model looks much like a sophisticated DSO: centralized revenue-cycle management, HR, procurement, payer negotiation, and marketing, with practices held to a minimum profile (MB2 says it typically partners with practices above $1.25 million in revenue and four-to-five operatories).¹ The differentiator is the ownership and governance layer, not the service menu.

On revenue drivers: practice-level patient services remain the economic engine, with residual profit split between doctor and MB2 by equity stake after centralized service charges. The company reports that revenue and EBITDA have each grown more than 30% per year since Charlesbank's 2021 investment, with 450-plus partnerships added over that span — a company-reported, promotional figure.¹ Independent coverage has floated an estimated ~$300 million of EBITDA and, notably, has characterized the 2024 Warburg transaction as a high-yield pay-in-kind note funding a shareholder distribution rather than a straightforward equity infusion — a framing that differs from the company's "strategic equity" language and is worth diligence for any investor evaluating the capital structure.²

Technology & Software Ecosystem

Public information on MB2's technology is thinner than on its finances, and the gaps are themselves informative. MB2 has not publicly standardized on a single practice-management system (PMS). Its analytics partner, Jarvis Analytics, describes integrating data across "different practice management systems" for MB2 — strong evidence that the network runs a heterogeneous, multi-PMS environment inherited through acquisitions, with Jarvis acting as the unifying data layer for KPIs like production, collections, and new-patient counts.²

The clearest documented pieces of the stack are: Jarvis Analytics (multi-practice performance dashboards); Cerebro, a proprietary HIPAA-compliant intranet and app ecosystem built with intranet vendor Haystack, where partner practices can review KPIs and financial documents; a Microsoft 365– and Azure–based hybrid cloud; and Inside Desk for revenue-cycle automation (claim-status checks, EOB downloads).¹ Job postings point to a hybrid internal-IT-plus-managed-service-provider model supporting a 24/7 distributed clinical environment. What MB2 does not disclose — and what investors should not assume — are the specific chairside, imaging, or PMS vendors standardized across practices; there is no public evidence of a single enforced clinical platform. The takeaway: MB2's tech bet is on a data and integration layer over a deliberately diverse base, not on rip-and-replace standardization.

Competitive Landscape

MB2 competes directly with the largest DSOs even as it brands itself differently. Among the five platforms investors most often compare, late-2025 scale looked roughly like this (location figures are company-reported and not strictly comparable, since "practices" and "offices" are defined differently across organizations):⁴

• Heartland Dental — ~1,800–1,900+ supported offices across 39 states plus DC; majority-owned by KKR. The largest, and the most conventional DSO.
• Aspen Dental (within The Aspen Group) — ~1,000–1,429 locations; backed by Leonard Green & Partners and Ares Management.
• PDS Health (Pacific Dental Services) — 1,000+ supported practices across ~25 states; notably dentist-owned, standing apart from the PE-controlled majority.
• MB2 Dental — 800+ practices across 45 states; Warburg Pincus + Charlesbank.
• Smile Brands — 600+ offices across ~29 states; backed by Gryphon Investors.

By location count, MB2 is clearly smaller than Heartland, Aspen, and PDS, but larger than Smile Brands — squarely the #4 of the top five. Its distinguishing feature is ownership: of the largest U.S. DSOs, most are PE-controlled at the corporate level, and only PDS Health is described as dentist-owned. MB2 threads the needle, pairing institutional sponsorship with doctor co-ownership at the practice level — a positioning explicitly designed to win dentists who are wary of selling outright to a corporate chain. Whether that culture difference is durable as the network crosses 800 practices and multiple sponsor cycles is the open competitive question.

Market Position

MB2 occupies a defensible middle position. It is large enough to capture the procurement, payer, and technology scale economies that justify consolidation, yet it has differentiated itself in the talent market — arguably the binding constraint in dentistry — by offering equity rather than employment. With roughly 16% of U.S. dentists DSO-affiliated by the mid-2020s (and over a quarter of recent graduates),³ the runway for continued consolidation is real, and MB2's reported 30%+ annual revenue and EBITDA growth suggests it has been taking share faster than the more mature, larger platforms.

The risks are equally legible. MB2 is a leveraged platform — the ~$2.344 billion KKR facility and continued unitranche borrowing mean rate sensitivity and refinancing risk sit alongside the growth story. The "doctor-equity" promise is harder to sustain culturally at 1,900 doctors than at 100, and the absence of disclosed equity splits makes the alignment claim difficult to audit from the outside. And the divergence between the company's "strategic equity" framing and third-party "PIK-note distribution" framing of the 2024 deal is exactly the kind of detail a diligent investor would want resolved before underwriting the headline valuation.

TMR Take: MB2's DPO model is a genuine structural innovation, not just a rebrand — letting dentists keep practice-level equity is a real recruiting moat in a labor-constrained industry, and three sponsors and a $3.5B-plus valuation say the market believes the growth. But "partnership" is a brand, not a guarantee: the equity split is undisclosed, the operating model is a sophisticated DSO underneath, and the network is leveraged. For operators weighing a partner, MB2's pitch is the most autonomy-preserving of the big platforms — but get the equity percentage, the parent-company terms, and the recap mechanics in writing. For vendors, MB2's heterogeneous, multi-PMS environment (unified by Jarvis) means there is no single switch to flip — selling in is a practice-by-practice or data-layer conversation, not one central RFP. For investors, MB2 is a high-growth, well-sponsored asset whose headline numbers are almost entirely company-reported; the diligence priorities are the true location count behind the "practice" figure, the EBITDA and leverage picture, and the substance behind the 2024 transaction structure.

Sources

1. MB2 Dental — company website, press releases, milestone and partnership announcements, and year-end results.

2. Industry and trade reporting / deal coverage — Group Dentistry Now, Business Wire, PE Hub, and analytics partner Jarvis Analytics.

3. Third-party market and financial analysis — Preqin and CB Insights.

4. The Molar Report analysis.